Vaccines Clinical Trials

T-Cell Response to Vaccination

The purpose of this study is to see how your body responds to a vaccine and how your body forms a protective response after vaccination. In this study we will use the yellow fever vaccine, an FDA approved vaccine that is commonly given to people traveling to certain parts of …

A5369: HIV-1-Gag Conserved-Element DNA Vaccine (p24CE) as Therapeutic Vaccination in HIV-Infected Persons with Viral Suppression on Antiretroviral Therapy

A5369 is a phase I/IIa, randomized, double-blind, placebo-controlled study to evaluate the safety, immunogenicity, and efficacy of p24CE/full-length Gag DNA, as a therapeutic vaccine in HIV-1 infected persons. The study targets to enroll 40 participants. All participants are well-suppressed on ART, current CD4 T cell counts greater than 500 cells/mm3, …

Lymph Node Fine Needle Aspiration to Study Immune Responses to Vaccinations

By studying lymph node cells, we hope to learn more about how vaccines work, including new vaccines such as ones developed against the COVID-19 virus. What we learn may help us make more effective vaccines in the future.

Substudy: Understanding COVID-19 vaccine responses in the setting of immunotherapy

Responses of Tfh and B cells can be identified in peripheral blood following administration of other vaccines, but whether different SARS-Cov2 vaccines induce Tfh and how these Tfh responses relate to B cell responses, induction of antibody and durability of cellular and humoral immunity over time is unclear.

Characterizing SARS-CoV-2-specific Immunity in Individuals Who Have Recovered From COVID-19  

A main aim of HVTN 405/HPTN 1901 is to develop antibody assays that can be reliably used to detect SARS-CoV-2 infection in vaccine and monoclonal antibody studies to prevent COVID-19. This information will be critical in illuminating the path to the development and testing of safe and effective vaccine and …

Profiling and Perturbing the Human Immune System to Understand the Human Immune Network

Following enrollment, patients (and healthy control subjects) will be vaccinated with IFV and/or pneumococcal vaccine based on established clinical guidelines, and these vaccinations will serve as secondary immune system perturbations.

None

None

None

None